share_log

Just Three Days Till China Meheco Group Co., Ltd. (SHSE:600056) Will Be Trading Ex-Dividend

Just Three Days Till China Meheco Group Co., Ltd. (SHSE:600056) Will Be Trading Ex-Dividend

距离中国医药集团股份有限公司(SHSE:600056)除权交易只有三天
Simply Wall St ·  06/22 21:40

Readers hoping to buy China Meheco Group Co., Ltd. (SHSE:600056) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least two business day to settle. Therefore, if you purchase China Meheco Group's shares on or after the 27th of June, you won't be eligible to receive the dividend, when it is paid on the 27th of June.

希望购买中国医药股份有限公司(SHSE:600056)的分红的读者们需要尽快采取行动,因为这只股票即将进行除息。除息日是公司股权登记日前的一个工作日,亦即公司确定哪些股东有权获得分红的日期。除息日的影响是巨大的,因为无论何时买入或卖出一只股票,交易都需要至少两个交易日才能结算。因此,如果您在6月27日或之后购买中国医药的股票,当它于6月27日支付分红时,您将无法获得分红。

The company's next dividend payment will be CN¥0.21019 per share. Last year, in total, the company distributed CN¥0.21 to shareholders. Last year's total dividend payments show that China Meheco Group has a trailing yield of 2.0% on the current share price of CN¥10.40. If you buy this business for its dividend, you should have an idea of whether China Meheco Group's dividend is reliable and sustainable. We need to see whether the dividend is covered by earnings and if it's growing.

该公司下一个分红为每股人民币0.21019元。去年,公司总共向股东分配了人民币0.21元的分红。去年的总分红额表明,中国医药在当前人民币10.40元的股票价格下具有2.0%的年度回报率。如果您因分红而购买这家公司,您需要了解中国医药的分红是否可靠和可持续。我们需要查看分红是否被盈利覆盖以及是否在增长。

If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. That's why it's good to see China Meheco Group paying out a modest 34% of its earnings. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Thankfully its dividend payments took up just 46% of the free cash flow it generated, which is a comfortable payout ratio.

如果公司支付的股息比它赚的更多,那么股息可能变得不可持续,这绝非理想情况。这就是为什么看到中国医药支付的股息仅占盈利的适度34%是一个好兆头。然而,现金流通常比利润更重要,用于评估股息的可持续性,因此我们应该始终检查公司是否产生了足够的现金来支付其股息。值得庆幸的是,它的分红支付只占其自由现金流的46%,这是一个舒适的支付比率。

It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.

看到股息既有盈利也有现金流的覆盖是令人鼓舞的。这通常表明股息是可持续的,只要收益没有急剧下降。

Click here to see how much of its profit China Meheco Group paid out over the last 12 months.

单击此处,了解中国医药过去12个月的利润分配情况。

historic-dividend
SHSE:600056 Historic Dividend June 23rd 2024
SHSE:600056历史分红6月23日2024年

Have Earnings And Dividends Been Growing?

收益和股息一直在增长吗?

When earnings decline, dividend companies become much harder to analyse and own safely. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. China Meheco Group's earnings per share have fallen at approximately 9.7% a year over the previous five years. When earnings per share fall, the maximum amount of dividends that can be paid also falls.

当收益下降时,分红公司变得更加难以分析和安全持有。如果业务进入低谷并且分红被削减,公司的价值可能会急剧下降。中国医药的每股收益在过去五年中每年下降约9.7%。当每股收益下降时,可以支付的最大股息金额也会下降。

Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. In the last 10 years, China Meheco Group has lifted its dividend by approximately 7.4% a year on average.

许多投资者会通过评估股息支付在相当长一段时间内的变化来评估公司的股息表现。在过去的10年中,中国医药的股息平均每年增长约7.4%。

The Bottom Line

还有一件事需要注意的是,我们已经确定了上海医药的2个警告信号,了解这些信号应该成为你的投资过程的一部分。

From a dividend perspective, should investors buy or avoid China Meheco Group? Earnings per share are down meaningfully, although at least the company is paying out a low and conservative percentage of both its earnings and cash flow. It's definitely not great to see earnings falling, but at least there may be some buffer before the dividend needs to be cut. In summary, while it has some positive characteristics, we're not inclined to race out and buy China Meheco Group today.

从分红的角度来看,投资者应该买入还是避开中国医药?每股收益显著下降,尽管公司的盈利和现金流支付比率都低且保守,这绝非好事。收益下降肯定不是什么好现象,但至少在削减分红之前可能有一些缓冲。总之,尽管它具有一些积极的特点,但我们并不倾向于今天就买入中国医药。

While it's tempting to invest in China Meheco Group for the dividends alone, you should always be mindful of the risks involved. We've identified 3 warning signs with China Meheco Group (at least 1 which is a bit concerning), and understanding them should be part of your investment process.

虽然单纯为了分红而投资中国医药很有吸引力,但您应该始终注意所涉及的风险。我们已经确定了中国医药的3个警示信号(至少有1个令人担忧),了解它们应该成为您的投资过程的一部分。

Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.

一般来说,我们不建议仅仅购买第一个股息股票。下面是一个经过策划的有趣的、股息表现良好的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,也可以发送电子邮件至editorial-team@simplywallst.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发